Baricitinib
Back to searchMolecule Structure
Scientific Name
Baricitinib
Description of the Drug
Baricitinib is a Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11817
http://www.drugbank.ca/drugs/DB11817
Brand Name(s)
Olumiant
Company Owner(s)
Eli Lilly And Co
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tyrosine-protein kinase JAK1 | SINGLE PROTEIN | INHIBITOR | CHEMBL2835 |
| Tyrosine-protein kinase JAK2 | SINGLE PROTEIN | INHIBITOR | CHEMBL2971 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL871150 | |
| Human Metabolome Database | HMDB0248873 | |
| DrugBank | DB11817 | |
| PubChem: Thomson Pharma | 85205106 | |
| PubChem | 44205240 | |
| LINCS | LSM-6709 | |
| Nikkaji | J3.196.953K | |
| PDBe | 3JW | |
| BindingDB | 50021656 | |
| EPA CompTox Dashboard | DTXSID30152228 | |
| DrugCentral | 5202 | |
| ChemicalBook | CB82620596 | |
| Guide to Pharmacology | 7792 | |
| rxnorm | BARICITINIB | OLUMIANT |
| ChEBI | 95341 | |
| ZINC | ZINC000073069247 |
